Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)

Blood (2019) 134 (Supplement_1): 322.

https://doi.org/10.1182/blood-2019-124590

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 2809.

https://doi.org/10.1182/blood-2019-129391

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

90Y-Ibritumomab-Tiuxetan Consolidation in First-Line Complete Response Follicular Lymphoma Patients. Single Center Outcomes Analysis after Five Years Median Follow-up

Marcio Andrade-Campos, MD PhD, Natalia Espinosa-Lara, MD, Paola Lievano, MD PhD, Luis Lopez-Gomez, MD PhD, Teresa Baringo, MD, Pilar Giraldo, MD PhD

Blood (2016) 128 (22): 5323.

https://doi.org/10.1182/blood.V128.22.5323.5323

Published: 2016

Journal Articles

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Blood (2015) 126 (23): 5108.

https://doi.org/10.1182/blood.V126.23.5108.5108

Published: 2015

Journal Articles

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Amrita Y. Krishnan, MD, Joycelynne Palmer, PhD, Auayporn P. Nademanee, MD, Robert Chen, Leslie L. Popplewell, MD, Nicole Tsai, MS, James F. Sanchez, PhD, Jennifer Simpson, Ricardo Spielberger, MD, Dave Yamauchi, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 3179.

https://doi.org/10.1182/blood.V126.23.3179.3179

Published: 2015

Journal Articles

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Blood (2015) 126 (23): 3192.

https://doi.org/10.1182/blood.V126.23.3192.3192

Published: 2015

Journal Articles

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Simone Ferrero, Alessandro Pastore, Roswitha Forstpointner, M.D., Christian W. Scholz, Antonio Pezzutto, Lothar Bergmann, Lorenz Truemper, Juergen Finke, Ulrich Keller, Marco Ladetto, Wolfgang Hiddemann, M.D., Oliver Weigert, Michael Unterhalt, Martin Dreyling

Blood (2013) 122 (21): 4384.

https://doi.org/10.1182/blood.V122.21.4384.4384

Published: 2013

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Soham D. Puvvada, MD, Daniel O. Persky, MD, Lora Inclan, Jonathan H. Schatz, MD, Ellen M Chase, Jose Guillen, D Roe, Thomas P. Miller, MD

Blood (2013) 122 (21): 4404.

https://doi.org/10.1182/blood.V122.21.4404.4404

Published: 2013

Journal Articles

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Zijun Y Xu-Monette, MD, Gabriela Rondon, MD, Rosamar Valverde, MD, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Paolo Anderlini, MD, Ahmed Sairah, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Partow Kebriaei, MD, Luis E Fayad, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Richard E Champlin, MD, Ken H. Young, MD, PhD

Blood (2013) 122 (21): 3350.

https://doi.org/10.1182/blood.V122.21.3350.3350

Published: 2013

Journal Articles

RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years.

Marcio M Andrade, Sr., MD, Anel Montes, MD, Ilda Murillo, MD, Jose M Grasa, Sr., MD, Teresa Baringo, MD, PhD, Pilar Giraldo, MD, PhD

Blood (2012) 120 (21): 2742.

https://doi.org/10.1182/blood.V120.21.2742.2742

Published: 2012

Journal Articles

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Hossein Borghaei, DO, MS, Russell J. Schilder, MD, Samuel Litwin, PhD, Michael Millenson, MD, Adam D Cohen, MD, Linda Thibodeau, RN, Mitchell R Smith, MD, PhD

Blood (2012) 120 (21): 2753.

https://doi.org/10.1182/blood.V120.21.2753.2753

Published: 2012

Journal Articles

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Dominik Schneidawind, MD, Sebastian Jendryssek, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 4482.

https://doi.org/10.1182/blood.V120.21.4482.4482

Published: 2012

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients

Anna Vanazzi, Chiara Grana, Daniele Laszlo, Marco Chinol, Mara Negri, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli

Blood (2012) 120 (21): 4876.

https://doi.org/10.1182/blood.V120.21.4876.4876

Published: 2012

Journal Articles

Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma

Christophe Fruchart, MD, Josette Briere, MD, Renaud Ciappuccini, MD, Olivier Casasnovas, MD, Herve Tilly, MD, Franck Morschhauser, Catherine Sebban, MD, Gilles Salles, MD, Christophe Ferme, MD, Achiel Van Hoof, Dominique Bordessoule, Reda Bouabdallah, MD, Alain Delmer, MD, Christian Gisselbrecht, MD

Blood (2012) 120 (21): 812.

https://doi.org/10.1182/blood.V120.21.812.812

Published: 2012

Journal Articles

RIT with 90Y Ibritumomab Tiuxetan in Agressive Non-Hodgkin Lymphoma. Evaluation of Recent Outcomes in a Single Institution

Anel Montes, MD, Ma Andrade, Ilda Murillo, MD, Luis Lopez-Gomez, Teresa Baringo, MD, PhD, Pilar Giraldo

Blood (2012) 120 (21): 4883.

https://doi.org/10.1182/blood.V120.21.4883.4883

Published: 2012

Journal Articles

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Lisa Zipp, MS, Rima M Saliba, Ph.D., Rosamar Valverde, Grace-Julia Okoroji, Martin Korbling, MD, Barry I Samuels, MD, Lynne V. Abruzzo, MD, PhD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Bill Erwin, MS, Paolo Anderlini, MD, Uday R Popat, MD, Partow Kebriaei, Homer A Macapinlac, MD, Richard Champlin, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 2005.

https://doi.org/10.1182/blood.V118.21.2005.2005

Published: 2011

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center,

Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, R.N, Seongsoo Jang, MD, Chan-Jeoung Park, MD, Hyun Sook Chi, Chan-Sik Park, Jooryung Huh, MD, Sang-wook Lee, Cheolwon Suh, MD

Blood (2011) 118 (21): 3703.

https://doi.org/10.1182/blood.V118.21.3703.3703

Published: 2011

Journal Articles

Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study

G. Pica, S. Nati, Umberto Vitolo, MD, Sara Galimberti, Pier Luigi Zinzani, MD, PhD, Nicola Cascavilla, Mario Petrini, MD, A. M. Carella, MD

Blood (2011) 118 (21): 100.

https://doi.org/10.1182/blood.V118.21.100.100

Published: 2011

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) in Combination with a Fludarabine-Based Reduced Conditioning Regimen (RIC) Followed by Allogenic Stem Cell Transplantation for Advanced/Aggressive Non-Hodgkin's Lymphoma (NHL): A Prospective, Multicentre, Open Phase II Study

Krimo Bouabdallah, MD, Sabine Furst, MD, Reda Bouabdallah, MD, Stephane Vigouroux, MD, Reza Tabrizi, MD, Cyril Melot, Steven Le Gouill, MD, PhD, Nathalie Fegueux, Olivier Tournilhac, MD, PhD, Mohamad Mohty, Didier Blaise, MD, noel-Jean Milpied, MD

Blood (2011) 118 (21): 3027.

https://doi.org/10.1182/blood.V118.21.3027.3027

Published: 2011

NARROW

Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

90Y-Ibritumomab-Tiuxetan Consolidation in First-Line Complete Response Follicular Lymphoma Patients. Single Center Outcomes Analysis after Five Years Median Follow-up

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years.

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients

Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma

RIT with 90Y Ibritumomab Tiuxetan in Agressive Non-Hodgkin Lymphoma. Evaluation of Recent Outcomes in a Single Institution

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center,

Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) in Combination with a Fludarabine-Based Reduced Conditioning Regimen (RIC) Followed by Allogenic Stem Cell Transplantation for Advanced/Aggressive Non-Hodgkin's Lymphoma (NHL): A Prospective, Multicentre, Open Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only